Overslaan en naar de inhoud gaan

 Wetenschapelijke artikelen

Factors associated with SARS-CoV-2 infection and outcome in patients with solid tumors or hematological malignancies: a single-center study.

Auteurs : Goudsmit A, Cubilier E, Meert AP, Aftimos P, Stathopoulos K, Spilleboudt C, Loizidou A
Jaar : 2021
Journal : Support Care Cancer

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.

Auteurs : Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, OShaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS
Jaar : 2021
Journal : N Engl J Med
Volume : 384
Pagina's : 1529-1541

Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors.

Auteurs : Hellmann MD, Bivi N, Calderon B, Shimizu T, Delafontaine B, Liu ZT, Szpurka AM, Copeland V, Hodi FS, Rottey S, Aftimos P, Piao Y, Gandhi L, Galvao VR, Leow CC, Doi T
Jaar : 2021
Journal : Clin Cancer Res

Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.

Auteurs : Lebbé C, Italiano A, Houédé N, Awada A, Aftimos P, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Raymond E, Faivre S, Pages C, Gomez-Roca C, Schueler A, Goodstal S, Massimini G, Delord JP
Jaar : 2021
Journal : Target Oncol
Volume : 16
Pagina's : 47-57

Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.

Auteurs : Delord JP, Italiano A, Awada A, Aftimos P, Houédé N, Lebbé C, Pages C, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Faivre S, Gomez-Roca C, Scheuler A, Massimini G, Raymond E
Jaar : 2021
Journal : Target Oncol
Volume : 16
Pagina's : 37-46

Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients.

Auteurs : Bohlok A, Vermeulen P, Leduc S, Latacz E, Botzenhart L, Richard F, De Schepper M, Geukens T, Lucidi V, Ignatiadis M, Aftimos P, Sotiriou C, Piccart-Gebhart M, Hendlisz A, Van Laere S, Dirix L, Noël JC, Biganzoli E, Larsimont D, Desmedt C, Donckier V
Jaar : 2020
Journal : NPJ Breast Cancer
Volume : 6
Pagina's : 64

Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. <i>

Auteurs : Krayem M, Aftimos P, Najem A, Hooven TVD, Berg AVD, Hovestad-Bijl L, Wijn R, Hilhorst R, Ruijtenbeek R, Sabbah M, Kerger J, Awada A, Journe F, Ghanem G
Jaar : 2020
Journal : Cancers (Basel)
Volume : 12

A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using <sup>18</sup>F-FES PET/CT imaging.

Auteurs : Jager A, de Vries EGE, der Houven van Oordt CWM, Neven P, Venema CM, Glaudemans AWJM, Wang Y, Bagley RG, Conlan MG, Aftimos P
Jaar : 2020
Journal : Breast Cancer Res
Volume : 22
Pagina's : 97

Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms.

Auteurs : Saini KS, de Las Heras B, Plummer R, Moreno V, Romano M, de Castro J, Aftimos P, Fredriksson J, Bhattacharyya GS, Olivo MS, Schiavon G, Punie K, Garcia-Foncillas J, Rogata E, Pfeiffer R, Orbegoso C, Morrison K, Curigliano G, Chin L, Saini ML, Rekdal Ø, Anderson S, Cortes J, Leone M, Dancey J, Twelves C, Awada A
Jaar : 2020
Journal : JCO Glob Oncol
Volume : 6
Pagina's : 1357-1362